|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Kite outperformed med stocks Tuesday, gapping up on lymphoma trial results even as Perrigo and Tenet stocks fell by double digits.
Ionis (IONS) entered into a collaboration agreement with Novartis (NVS) for the development and commercialization of AKCEA-APO(a)-L and AKCEA-APOCIII-L.
Ionis stock popped Friday on a $100 million investment from Novartis in a development agreement for two early-stage cardiovascular drugs.
The U.S. Food and Drug Administration approved in late December Ionis Pharmaceuticals Inc 's (NASDAQ: IONS ) therapy for the treatment of spinal muscular atrophy called Spinraza. In a research report on ...
Novartis has agreed with Ionis Pharmaceuticals Inc and its affiliate Akcea Therapeutics Inc to license two experimental cardiovascular treatments in a deal which Ionis said could eventually be worth more than $1 billion. The treatments aim to reduce cardiovascular risk in patients with high levels of lipoproteins. The therapies called AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx have the potential to lower lipoproteins Lp(a) and ApoCIII by up to 90 percent, Novartis said in a statement on Friday.
RBC Capital Markets biotech analyst Michael Yee takes a swivel-headed approach to fundamental research.
Ionis (IONS) announced positive data from a phase II study on IONIS-GCGR for the treatment of patients with type II diabetes.
Ionis stock toppled Thursday on a two-day downtrend as investors siphoned off gains that followed FDA approval of a key spinal disease drug.
A new drug called Spinraza (generic name: nusinersen) treats a rare disease, spinal muscular atrophy, that is the leading cause of genetic death in infants. It could be a blockbuster for makers Biogen and Ionis.
Ionis Pharmaceuticals, Inc. (IONS) announced that it has earned $5 million milestone payment from Janssen Biotech, Inc., a pharmaceutical division of Johnson & Johnson (JNJ).
Ionis (IONS) received $28 million from AstraZeneca (AZN) following the completion of IND-supporting studies and licensing of IONIS-KRAS-2.5.